The association between the apolipoprotein A1/ high density lipoprotein -cholesterol and diabetes in Taiwan — a cross-sectional study

BMC Endocrine Disorders

Yung-Po Liaw⁵  Chien-Jen Chen²  Yi-Chen Chiang³  Chia-Yo Ho³  Chien-Chang Ho⁴  Jing-Yang Huang³  Yi-Hua Sun¹  Pei-Chieh Ko³  Chia-Chi Lung⁵  Zhi-Hong Jian³ 

[1] Department of Dentistry, Chung Shan Medical University, Taichung 40201, Taiwan;Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan;Department of Public Health and Institute of Public Health, Chung Shan Medical University, Taichung City, Taiwan;Department of Health and Leisure Management, Yuanpei University, Hsinchu, Taiwan;Department of Family and Community Medicine, Chung Shan Medical, University Hospital, Taichung City 40201, Taiwan

关键词: Diabetes;    Low density lipoprotein-cholesterol;    High density lipoprotein-cholesterol;    Apolipoprotein B;    Apolipoprotein A1;   

Others  :  1085616
DOI  :  10.1186/1472-6823-13-42

 received in 2013-02-05, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Traditional lipid indices have been associated with type 2 diabetes, but it remains uncertain which lipid index is the best discriminator for diabetes. In this study, we aimed to assess lipoproteins, traditional lipid variables, and other variables to discover their association with diabetes in the Taiwanese population.

Methods

Data from a nationwide cross-sectional population-based survey of 3087 men and 3373 women in 2002 were analyzed in this study. All participants were assessed for anthropometry, glycosylated hemoglobin, fasting sugar and lipid profiles with triglycerides, high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), and apolipoprotein A1 (ApoA1) and B (ApoB). The ratio of LDL-C/HDL-C, ApoB/ApoA1, ApoB/LDL-C and ApoA1/HDL-C and other variables were analyzed to determine their potential roles in type 2 diabetes in the Taiwanese population. The Odds ratios (ORs) of the risk variables for diabetes were estimated using logistic regression and were adjusted for confounding factors.

Results

The increased ratio of ApoA1/HDL-C was significantly associated with diabetes in men (top tertile vs. lowest: OR 2.98; 95% CI: 1.12 - 7.92; P-trend = 0.030) and women (top tertile vs. lowest: OR 2.15; 95% CI: 1.00 - 4.59; P-trend = 0.047). A modest increased diabetic risk was evident with ApoB/LDL-C in women (top tertile vs. lowest: OR 2.03; 95% CI: 1.07- 3.85; P-trend = 0.028), but not in men (top tertile v. lowest: OR 1.69; 95% CI: 0.79- 3.62; P-trend = 0.198).

Conclusions

ApoA1/HDL-C had a significant linear association with diabetes in both sexes and was superior to other lipid and lipoprotein variables among the general Taiwanese population.

【 授权许可】

   
2013 Jian et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Chang CH, Shau WY, Jiang YD, Li HY, Chang TJ, Sheu WH, Kwok CF, Ho LT, Chuang LM: Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999–2004: a national health insurance data set study. Diabet Med 2010, 27(6):636-643.
• [2]AMERICAN DIABETES ASSOCIATION: Standards of medical care for patients with diabetes mellitus. Diabetes care 2003, 26(Suppl 1):S33-S50.
• [3]Luijks H, Schermer T, Bor H, Van Weel C, Lagro-Janssen T, Biermans M, De Grauw W: Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Med 2012, 10:128. BioMed Central Full Text
• [4]Collins GS, Mallett S, Omar O, Yu LM: Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med 2011, 9:103. BioMed Central Full Text
• [5]Gotto AM Jr: Apolipoproteins and metabolism in atherosclerosis. Trans Am Clin Climatol Assoc 1990, 101:46-57. discussion 57–48
• [6]Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G: The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010, 142(1):72-79.
• [7]Seo MH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Lee WY: Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. J Clin Endocrinol Metab 2011, 96(12):E2050-E2054.
• [8]Bardini G, Dicembrini I, Rotella CM, Giannini S: Correlation between HDL cholesterol levels and beta-cell function in subjects with various degree of glucose tolerance. Acta diabetol 2013, 50:277-281.
• [9]Sung KC, Hwang ST: Association between insulin resistance and apolipoprotein B in normoglycemic Koreans. Atherosclerosis 2005, 180(1):161-169.
• [10]Ying X, Qian Y, Jiang Y, Jiang Z, Song Z, Zhao C: Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta diabetol 2012, 49(6):465-472.
• [11]Shih YT HY, Chang HY, Liu JP, Lin HS, Chang MC: The design, contents, operation and the characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health 2004, 22:419-430.
• [12]Wen CP, Levy DT, Cheng TY, Hsu CC, Tsai SP: Smoking behaviour in Taiwan, 2001. Tob Control 2005, 14(Suppl 1):i51-55.
• [13]Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, Chen HJ, Pan WH, Tseng CH, Cheng SH, et al.: Evidence for improved control of hypertension in Taiwan: 1993–2002. J Hypertens 2008, 26(3):600-606.
• [14]World Health Organization: Physical status: the use and interpretation of anthropometry. Geneva: WHO; 1995.
• [15]American Diabetes Association: Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes care 2010, 33(Suppl 1):S3.
• [16]Ginsberg HN: Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996, 45(Suppl 3):S27-30.
• [17]Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, Hegele RA, Zinman B, Hanley AJ: Utility of non-high-density lipoprotein cholesterol in assessing incident type 2 diabetes risk. Diabetes Obes Metab 2012, 14(9):821-825.
• [18]Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, Hegele RA, Zinman B, Hanley AJ: Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. Clin Chem 2010, 56(4):666-670.
• [19]Belfki H, Ben Ali S, Bougatef S, Ben Ahmed D, Haddad N, Jmal A, Abdennebi M, Ben Romdhane H: The Apolipoprotein B/Apolipoprotein A 1 ratio in relation to metabolic syndrome and its components in a sample of the Tunisian population. Exp Mol Pathol 2011, 91(2):622-625.
• [20]Krauss RM: Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994, 5(5):339-349.
• [21]Goldberg IJ: Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001, 86(3):965-971.
• [22]Caixas A, Ordonez-Llanos J, De Leiva A, Payes A, Homs R, Perez A: Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 1997, 46(7):1207-1213.
• [23]Mykkanen L, Kuusisto J, Haffner SM, Laakso M, Austin MA: LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol 1999, 19(11):2742-2748.
• [24]Abate N, Vega GL, Garg A, Grundy SM: Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis 1995, 118(1):111-122.
• [25]Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000, 101(9):975-980.
• [26]Laws A, Hoen HM, Selby JV, Saad MF, Haffner SM, Howard BV: Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 1997, 17(1):64-71.
• [27]Al-Bahrani AI, Bakhiet CS, Bayoumi RA, Al-Yahyaee SA: A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. Diabetes Res Clin Pract 2005, 69(1):44-51.
• [28]Wagner AM, Jorba O, Rigla M, Alonso E, Ordonez-Llanos J, Perez A: LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes. Acta Diabetol 2002, 39(4):215-220.
• [29]Onat A, Can G, Cicek G, Ayhan E, Dogan Y: Predictive value of serum apolipoprotein B/LDL-cholesterol ratio in cardiometabolic risk: population-based cohort study. Clin Biochem 2010, 43(18):1381-1386.
• [30]Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36(2):211-228.
• [31]Miller NE, Thelle DS, Forde OH, Mjos OD: The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case–control study. Lancet 1977, 1(8019):965-968.
• [32]Koropatnick TA, Kimbell J, Chen R, Grove JS, Donlon TA, Masaki KH, Rodriguez BL, Willcox BJ, Yano K, Curb JD: A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-american men. J Gerontol A Biol Sci Med Sci 2008, 63(11):1235-1240.
• [33]Brunzell JD, Sniderman AD, Albers JJ, Kwiterovich PO Jr: Apoproteins B and A-I and coronary artery disease in humans. Arteriosclerosis 1984, 4(2):79-83.
• [34]Toth PP, Davidson MH: High-density lipoproteins: marker of cardiovascular risk and therapeutic target. J Clin Lipidol 2010, 4(5):359-364.
• [35]Nobecourt E, Tabet F, Lambert G, Puranik R, Bao S, Yan L, Davies MJ, Brown BE, Jenkins AJ, Dusting GJ, et al.: Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2010, 30(4):766-772.
• [36]Park KH, Shin DG, Kim JR, Hong JH, Cho KH: The functional and compositional properties of lipoproteins are altered in patients with metabolic syndrome with increased cholesteryl ester transfer protein activity. Int J Mol Med 2010, 25(1):129-136.
• [37]Schreier LE, Berg GA, Basilio FM, Lopez GI, Etkin AE, Wikinski RL: Lipoprotein alterations, abdominal fat distribution and breast cancer. Biochem Mol Biol Int 1999, 47(4):681-690.
• [38]Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, Hanson RL, Hill JO, Hubbard V, Kriska A, Stamm E, et al.: Relation of central adiposity and body mass index to the development of diabetes in the diabetes prevention program. Am J Clin Nutr 2008, 87(5):1212-1218.
• [39]Chien LY, Liou YM, Chen JJ: Association between indices of obesity and fasting hyperglycemia in Taiwan. Int J Obes Relat Metab Disord 2004, 28(5):690-696.
• [40]Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, De Lemos JA: Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308(11):1150-1159.
• [41]Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, Rimm E, Colditz GA: Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001, 161(13):1581-1586.
• [42]Cheng CH, Ho CC, Yang CF, Huang YC, Lai CH, Liaw YP: Waist-to-hip ratio is a better anthropometric index than body mass index for predicting the risk of type 2 diabetes in Taiwanese population. Nutr Res 2010, 30(9):585-593.
• [43]Chen CC, Wang WS, Chang HY, Liu JS, Chen YJ: Heterogeneity of body mass index, waist circumference, and waist-to-hip ratio in predicting obesity-related metabolic disorders for Taiwanese aged 35–64 y. Clin Nutr 2009, 28(5):543-548.